

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/773,861

02/01/2001

Gregory M. Landes

GA0182US

CONFIRMATION NO. 5135

FORMALITIES LETTER 1818 | 1818 | 1818 | 1818 | 1818 | 1818 | 1818 | 1818 | 1818 | 1818 | 1818 | 1818 | 1818 | 1818 | 1818 | 1818 |

CC000000007590976*

24536 GENZYME CORPORATION LEGAL DEPARTMENT 15 PLEASANT ST CONNECTOR FRAMINGHAM, MA 01701-9322

Date Mailed: 03/06/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

REC'D MAR 13 2002



Box Seq 45 03 CO PATENT Attorney Docket No. GA0182US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Landes, Gregory M.

APPLICATION NO:

09/773,861

GROUP NO: 1632

FILING DATE:

February 1, 2001

EXAMINER: Unassigned

TITLE:

ISOLATION AND IDENTIFICATION OF SECRETED PROTEINS

U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Box Sequence Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

RESPONSE TO MARCH 6, 2002 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Responsive to the above notice and pursuant to 37 C.F.R. § § 1.821 - 1.824 Applicant re-submits herewith a paper copy and a computer readable copy of the Sequence Listing for the above-identified application. Further to the formalities letter mailed March 6, 2002, a new diskette containing the sequence listing is submitted herewith.

Statement

I hereby state that (a) the content of the paper and computer readable copy submitted herewith are the same; (b) the content of the computer readable copy submitted herewith is the same as the Sequence Listing appearing on page 53 of the

In re: Landes

Application No. 09/773,861

Filed: February 1, 2001

Page 2

original specification of U.S. Provisional Application Serial Number 60/180,582 as filed on February 4, 2000 (now on page 41 of U.S. Application Serial Number 09/773,861 filed February 1, 2001); and (c) this submission includes no new matter.

Respectfully submitted,

Elizabeth Lassen

Registration No. 31,845

Genzyme Corporation 15 Pleasant Street Connector

P.O. Box 9322

Framingham, Massachusetts 01701-9322

Telephone: (508) 270-2553 Facsimile: (508) 872-5415